Completed PHASE3 INTERVENTIONAL 3-arm NCT00751881

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Sponsor: Sanofi

Conditions Multiple Sclerosis

Interventions Placebo Teriflunomide

Updated 7 times since 2017 Last updated: May 27, 2016 Started: Aug 31, 2008 Primary completion: Apr 30, 2012 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Sclerosis and is currently completed. Sanofi leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Athens, Greece , Bacau, Romania , Bamberg, Germany , Bangkok, Thailand , Bangkok Noi, Thailand , Baotou, China , Barcelona, Spain , Bayreuth, Germany , Bedford Park, Australia and 153 more locations